Research Reports | Market Assessment
October 2021

Prostate Cancer – Unmet Need – Detailed, Expanded Analysis – Metastatic Hormone Sensititve (US/EU)

The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer has evolved in recent years with the approval of hormonal agents such as Zytiga (Janssen), Xtandi (Pfizer / Astellas), and the next-generation androgen receptor inhibitor Erleada (Janssen). In December 2020, Orgovyx (Myovant / Takeda) was FDA approved and has also entered the treatment paradigm. Although novel treatment modalities have improved patient outcomes, substantial unmet need remains for novel therapies with better efficacy and improved safety and tolerability. Therefore, the therapeutic management of newly diagnosed metastatic hormone-sensitive prostate cancer presents an enormous commercial opportunity for drug developers.

QUESTIONS ANSWERED

  • What treatment drivers and goals are most likely to influence the choice of therapy for newly diagnosed metastatic hormone-sensitive prostate cancer?
  • What attributes are key influencers of prescribing, and what are the hidden opportunities for drug developers?
  • What are the prevailing areas of unmet need and opportunity in this patient population?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical therapy for newly diagnosed metastatic hormone-sensitive prostate cancer?

DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by our experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in June 2021.

Key companies: Janssen, Pfizer / Astellas, Myovant / Takeda.

Key drugs: Zytiga, Erleada, Xtandi, Orgovyx, Taxotere / docetaxel generics.

Table of contents

  • Prostate Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Hormone Sensititve (US/EU)
    • Executive Summary
      • Unmet Need - Metastatic Hormone-Sensitive Prostate Cancer - Executive Summary - October 2021
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Rationale for Drug Selection
          • Products for Metastatic Hormone-Sensitive Prostate Cancer and Rationale for Drug Selection
      • Treatment Drivers and Goals
        • Key Findings: Attribute Importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Medical Oncologists' Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer
        • Importance of Efficacy Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Key Findings: Stated vs. Derived Importance
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: Europe
      • Product Performance Against Treatment Drivers and Goals
        • Key Findings
        • Overall Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Overall Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Mean Overall Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer: United States and Europe
        • Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Convenience of Administration Attributes: Europe
      • Assessment of Unmet Need
        • Key Findings: Unmet Need in Metastatic Hormone-Sensitive Prostate Cancer
        • Surveyed Medical Oncologistsu2019 Satisfaction with the Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Medical Oncologistsu2019 Satisfaction with the Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Key Findings: Unmet Need in Metastatic Hormone-Sensitive Prostate Cancer and Related Indications
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Metastatic Hormone-Sensitive Prostate Cancer and Related Indications: United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Metastatic Hormone-Sensitive Prostate Cancer and Related Indications: Europe
      • Opportunity Analysis
        • Areas of Opportunity in the Metastatic Hormone-Sensitive Prostate Cancer Market and Emerging Therapy Insights
          • Opportunity: A New Therapy That Can Prolong Overall Survival
          • Opportunity: A New Therapy That Delays Disease Progression and Skeletal-Related Events
          • Opportunity: A Novel Agent That Improves the Prostate-Specific Antigen Response Rate
          • Opportunity: A Novel Therapy With Improved Safety and Tolerability
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
          • Assigned Prohibitions for the Conjoint Module
        • Attribute Importance and Part-Worth Utilities
          • Metastatic Hormone-Sensitive Prostate Cancer Target Product Profile: Attribute Importance
          • Median Overall Survival (months)
          • Median Radiographic Progression-Free Survival (months)
          • Median Time to Skeletal-Related Events (months)
          • Incidence of Grade 3/4 Hypertension (% of patients)
          • Incidence of Any Grade Fatigue (% of patients)
          • Incidence of Any Grade Rash (% of patients)
          • Price per 28-Day Cycle ($)
        • Conjoint Analysis-Based Simulation of a Market Scenario
          • Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
          • Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
          • Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Market Simulation: Target Product Profiles Included in the Market Scenario
      • Appendix
        • Key Abbreviations
        • Bibliography
    Priyanka Mehra, B.Tech.
    Priyanka Mehra, B.Tech.

    Priyanka Mehra, B.Tech., is an analyst on the Oncology team at Clarivate. She has more than five years of experience working in pharmaceutical research and analytics, involving the management and execution of various strategic analysis projects for multiple oncology indications, secondary and primary research, and competitive intelligence. Previously, she worked as an associate consultant with Prescient Healthcare Group, where she was involved with biosimilar projects for global pharmaceutical clients and designed brand and commercial strategies in a variety of therapy areas, including oncology, immunology, and inflammatory disease. Prior to Prescient, she was a senior analyst at Smart Analyst, where she worked on indication prioritization and clinical landscapes for major oncology indications, including non-small-cell lung cancer, colorectal cancer, and melanoma. Ms. Mehra obtained her bachelor’s degree in biotechnology from Amity University in India.

    Login to access report
    Back to all Market Assessment reports
    Login to access report

    launch Related Market Assessment Reports